MedTrace Logo

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

NCT05769010 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-04-01

No results posted yet for this study

Summary

This study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases.

Conditions

Interventions

DRUG

SHR-A1811

SHR-A1811: intravenous

DRUG

Pyrotinib

Pyrotinib: oral

DRUG

Bevacizumab

Bevacizumab: intravenous

DRUG

Adebelizumab

Adebelizumab: intravenous

Sponsors & Collaborators

  • Henan Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2028-12-30
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05769010 on ClinicalTrials.gov